Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 21, 2020; 26(31): 4680-4693
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4680
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4680
Table 1 Basic clinical factors and computed tomography characteristics of the patients
Variable | Statistics, n (%) |
Gender | |
Male | 53 (69) |
Female | 24 (31) |
Median age (yr)1 | 64 (42-78) |
Morphological subtype | |
Medullary type | 34 (44) |
Mushroom type | 31 (40) |
Ulcer type | 12 (16) |
Narrowing type | 18 (23) |
Tumor length (mm)1 | 39.9 (10-118.9) |
Tumor location | |
Upper segment esophagus | 5 (6) |
Middle segment esophagus | 45 (58) |
Lower segment esophagus | 27 (35) |
Clinical symptom | |
Progressive dysphagia | 48 (62) |
Abdominal/retrosternal pain | 15 (20) |
Loss of appetite | 12 (15) |
Fever | 2 (3) |
Immunohistochemical result | |
CK | 57 (74) |
CgA | 25 (32) |
Syn | 63 (82) |
NSE | 22 (29) |
Ki-67 (%)1 | 80 (40-95) |
Thickness of esophageal tumor wall (mm)1 | 11 (2-27.93) |
Treatment strategy | |
Esophagectomy only | 9 (12) |
Chemotherapy | 1 (1) |
Chemo radiotherapy | 1 (1) |
Postoperative adjuvant chemoradiotherapy | 67 (87) |
Progression-free survival (mo)1 | 6.2 (0.3-45) |
Overall survival (mo)1 | 12.6 (0.9-64.8) |
- Citation: Zhou Y, Hou P, Zha KJ, Wang F, Zhou K, He W, Gao JB. Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study. World J Gastroenterol 2020; 26(31): 4680-4693
- URL: https://www.wjgnet.com/1007-9327/full/v26/i31/4680.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i31.4680